Skip to content
Study details
Enrolling now

Assess Fibrin in Brains With AD/ADRD

Massachusetts General Hospital
NCT IDNCT05336695ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1/2

Target enrollment

30

Study length

about 4.5 years

Ages

55–90

Locations

1 site in MA

What this study is about

This trial is testing a new imaging test called 64Cu-FBP8-PET to measure fibrin levels in the brains of people with Alzheimer's Disease or Dementia of Alzheimer Type. The goal is to see if there are differences in fibrin levels based on how far along the disease is.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take 64Cu-FBP8
  • 2.Undergo PET/MR Imaging

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Procedures

imaging

Devices

diagnostic

Body systems

Neurology